What are the opening hours?

Monday 10:30am - 6pm Tuesday 10:30am - 6pm Wednesday 10:30am - 6pm Thursday 10:30am - 6pm Friday 10:30am - 6pm Saturday 10:30am - 6pm

Fuda Cancer Hospital - India

Home
India
Vile Parle
Fuda Cancer Hospital - India

Fuda Cancer Hospital is famous for advance robotics & minimally invasive treatments. Cancer treatment varies from patient to patient.

It is located in Guangzhou (China) & have a consulting clinic and information centre in Mumbai (India). Fuda is committed to providing cancer patients around the world with the best medical care. Fuda Cancer Hospital is considered one of the BEST cancer hospitals in China by patients and is affiliated to Jinan University and Translational Medicine Center of Guangzhou Institute of Biomedicine and H

ealth of Chinese Academy of Sciences. As a tertiary hospital, Fuda operates with international standards and was selected as the National Key Clinical Specialty (Oncology) in 2010. In 2014, Fuda was accredited by the Joint Commission International (JCI), a golden standard of medical service worldwide. Fuda is equipped with 400 beds, 45 VIP rooms and 500 medical staffs to help our patients. Multiple Disciplinary Teams work in Fuda to personalize treatment for every single patient. Those teams include NanoKnife Ablation team (Irreversible Electroporation), Cryosurgical ablation team, cancer micro-vascular intervention team, combined immunotherapy team, and surgical team. Our clinical achievement and academic research are widely accepted by peer doctors and scientific journals. In Fuda, Doctors use more than 20 types of cancer treatment, including those mentioned above, to help our patient LIVE WITH CANCER as long as possible with a quality life. Fuda highly focuses on research and application of advanced clinical procedures and pays tremendous attention on patient care. In the past two decades, Fuda has been active in promoting Minimally Invasive Treatments such as Cryosurgery, NanoKnife, micro-vascular intervention treatment and Brachytherapy. Fuda was the first in China to introduce NanoKnife for clinical use and has accumulated substantial clinical experience. Patients are not just receiving treatment in Fuda, they live a life in Fuda with their family. To date, patients from over 110 countries were treated in Fuda and 50% of them are from South-East Asia, the Middle East, Oceania, Europe and North America. The number of patients treated in Fuda with Minimally Invasive treatments outnumbers any other hospital in the world. Fuda has received various awards in China and abroad for outstanding achievements in treating cancers and has been highly praised by patients worldwide.

24/07/2025

[Patient Stories] [Russia-Pancreatic Cancer-Cryoablation+Interventional Chemo+Immunotherapy]

Russian Man Crosses the Ocean to Battle the “King of Cancers”

A mere upper abdominal pain led to a diagnosis of advanced pancreatic cancer—with liver metastases. This was the harsh reality facing Igor (pseudonym).

Refusing Chemotherapy: Russian Cancer Patient Comes to China for Treatment
Igor is from Russia. Earlier this year, he began experiencing upper abdominal pain without any clear cause. A medical examination revealed masses in both the pancreas and liver. A liver biopsy suggested hepatic adenocarcinoma, most likely a metastasis from pancreatic cancer.
Refusing systemic chemotherapy, Igor was firm in his decision. He had seen too many pancreatic cancer patients suffer severe side effects from chemotherapy and feared that he might not survive them.
Yet treatment was urgent, as his liver pain was becoming unbearable. Igor turned to social media in search of medical solutions—and Guangzhou Fuda Cancer Hospital appeared in his research. After learning about Fuda’s medical technology and successful treatment cases involving pancreatic cancer, he made the decision to fly to Guangzhou, China, for treatment.
Fuda’s Multimodal Treatment Shrinks Tumors and Relieves Pain
Upon admission, Igor was in such severe pain that he could barely walk—he described himself as “dragging his body” into the hospital. Further examination revealed that in addition to tumors in the pancreas and liver, he also had tumor involvement in the peritoneum, omentum, and multiple lymph nodes.
Pancreatic cancer is known as the “king of cancers” not only because it’s hard to detect early and progresses rapidly, often with distant metastases, but also because of its complex tumor microenvironment, which causes significant immune resistance. This greatly limits the effectiveness of many existing treatment methods.
However, with advancements in medical technology, even pancreatic cancer with liver metastasis is no longer untreatable. Still, it requires a comprehensive, multimodal approach—single-modality treatments rarely yield satisfactory results.
The Department of Internal Medicine IV at Fuda developed a personalized treatment plan based on Igor’s condition, addressing his elevated amylase and transaminase levels with liver-protective, acid-suppressing, and pancreatic secretion-inhibiting therapies. Once those indicators stabilized, a personalized anti-tumor plan was initiated:
• Combination Immunotherapy and Targeted Therapy: These two treatments worked synergistically to enhance efficacy.
• Arterial Infusion Chemotherapy: Through femoral artery puncture and under DSA imaging guidance, a catheter was inserted to deliver chemotherapy directly into the celiac artery, hepatic artery, and superior mesenteric artery. This allowed direct targeting of the tumor while minimizing damage to liver function and the rest of the body—laying a solid foundation for future treatment.

After the initial immunotherapy and targeted therapy, Igor reported significant relief from liver pain. Two to three cycles later, CT scans showed a reduction in both the pancreatic lesions and multiple liver metastases. Fuda’s medical team promptly adjusted his treatment and performed cryoablation of liver tumors. Under imaging guidance, ablation probes were percutaneously inserted into the tumors, where rapid freezing and thawing cycles were used to precisely destroy cancer cells.
“I feel a bit weak right after treatment, but compared to being in so much pain I couldn’t walk, now I can go about life normally—even flying from place to place with energy.”

Since falling ill, Igor had lost 25 kg, but now his appetite has returned, and his weight remains stable. He expressed gratitude for choosing Fuda, especially praising its diverse treatment methods, attentive care, and the integration of traditional Chinese and Western medicine.
Ancient Wisdom for Modern Relief: Traditional Chinese Medicine Captures a Russian Heart
“TCM has been very kind to me.”When Igor first came to Fuda, he had never been exposed to Traditional Chinese Medicine (TCM), let alone imagined he would form a deep bond with it. But during his stay, he not only received advanced modern treatment, but also experienced the unique charm of TCM. After it effectively resolved his bowel issues and improved his vascular condition, this ancient medical wisdom completely won him over.

Igor fell in love with Fuda—and even more so with TCM. He became close friends with his TCM physician, Dr. Wang Xueliang, and left China with carefully prepared herbal medicine. Along with his newfound health, he brought home the warmth and friendship he found at Fuda to his distant homeland.

Click to learn more patient stories:
https://en.fudahospital.com/

You can contact us through the following channels:
☎️ TEL: +91 8850860970
🌟 WhatsApp: +91 8850860970
🌍 Website: https://fudahospital.in

20/07/2025

[Patient Stories] [Indonesia - Breast Cancer – Cryosurgery + Target medicine]

Indonesian Breast Cancer Patient with Multiple Metastasis: Pain Disappeared After Cryosurgery and Target Medicine

Click to learn more patient stories: https://en.fudahospital.com/

You can contact us through the following channels:
☎️ TEL: +91 8850860970
🌟 WhatsApp: +91 8850860970
🌍 Website: https://fudahospital.in/

17/07/2025

Pancreatic Cancer
It performs exocrine and endocrine functions. These enzymes are critical for protein, fat and carbohydrate digestion in the small intestine. If the pancreas is sick, like in the case of cancer, then those functions cannot be performed optimally. In this regard, pancreatic cancer brings about malabsorption syndromes, severe endocrine disorders like diabetes, accelerated breakdown of body systems, and possibly fatal multi-organ decline.

Read more: https://fudahospital.in/pancreatic-cancer/

.in

15/07/2025

[Fuda Cancer Hospital News] [NanoKnife]

President Niu Lizhi Appointed Vice Chairman of the China IRE (Irreversible Electroporation) Technology Innovation and Promotion Alliance

From July 11 to 13, 2025, the 2025 China Academic Conference on Minimally Invasive Oncology and the 25th Ablation Therapy Conference was successfully held in Beijing. The event was jointly organized by the Beijing Health Promotion Association, the Integrated Interventional Therapy Committee of the Chinese Anti-Cancer Association, the Minimally Invasive Oncology Committee of the Chinese Anti-Cancer Association, and the Interventional Minimally Invasive Therapy Committee of the Chinese Medical Education Association.

Over 200 renowned experts and scholars in the field of minimally invasive tumor treatment from across China gathered in Beijing for this prestigious event. Dr. Niu Lizhi, President of Guangzhou Fuda Cancer Hospital, was invited to attend and present.

On-Site at the Conference
Centered around the themes of Innovation, Intelligence, Integration, and Standardization, the conference featured multiple focused forums and lectures delivered by leading experts in the field.
During the "Combined Thermal and Cryoablation" session, Dr. Niu delivered a keynote presentation titled "Clinical Applications of the Comb-Knife", sharing in-depth insights and real-world clinical outcomes.
Later, at the "NanoKnife Tumor Ablation Session & Hands-On Training Workshop", Dr. Niu presented a series of representative cases involving multi-site tumor ablation using NanoKnife technology, supported by comprehensive clinical data. His presentation was not only rigorous and data-driven but also clear and accessible, earning high praise and recognition from fellow experts.

A significant milestone of this year’s conference was the official establishment of the China IRE (Irreversible Electroporation) Technology Innovation and Promotion Alliance.

Professor Xiao Yueyong from the First Medical Center of the PLA General Hospital was appointed as Chairman of the Alliance, while Dr. Niu Lizhi of Guangzhou Fuda Cancer Hospital was named Vice Chairman.
Dr. Niu remarked that China is now at the forefront globally in terms of both clinical experience and independent development of core equipment in the field of NanoKnife ablation for tumors. As early as July 2015, Fuda Cancer Hospital became the first institution in China to apply this technology to cancer treatment. To date, the hospital has successfully performed over 1,000 NanoKnife procedures.
His election as Vice Chairman not only reflects high-level recognition of Fuda’s achievements in NanoKnife tumor ablation but also serves as a strong motivation for the hospital to continue leading in medical innovation and technical excellence. Dr. Niu pledged to work hand-in-hand with fellow alliance members to promote the wider adoption and development of this cutting-edge technology, ultimately improving patient outcomes and enhancing quality of life.

🔗 Click to read more patient stories
https://en.fudahospital.com/

📞 Contact us via:
Phone: +91 8850860970
WhatsApp: +91 8850860970
Website: https://fudahospital.in

11/07/2025

[Patient Stories] [Russia-Pancreatic Cancer- Cryoablation + Interventional Chemo + Immunotherapy]

Why a Stage IV Pancreatic Cancer Patient Firmly Chose Fuda Cancer Hospital

Click to learn more patient stories:
https://en.fudahospital.com/

You can contact us through the following channels:
☎️ TEL: +91 8850860970
🌟 WhatsApp: +91 8850860970
🌍 Website: https://fudahospital.in/

08/07/2025

[Minimally invasive treatment] [Hilar metastatic lung nodules - Cryoablation]

Cryoablation for hilar metastatic lung nodules

Click to learn more patient stories:
https://en.fudahospital.com/

You can contact us through the following channels:
☎️ TEL: +91 8850860970
🌟 WhatsApp: +91 8850860970
🌍 Website: https://fudahospital.in/

06/07/2025

[Patient Story] [Indonesia – Advanced Metastatic Breast Cancer – Cryoablation + Gamma Knife Therapy]

Indonesian Advanced Breast Cancer Patient with Multiple Metastases Sees Tumor Shrink Nearly 50% in Just Two Months!

When people hear the word “advanced,” many assume it’s a death sentence—especially with widespread metastases. But that’s a misconception rooted in outdated thinking. With the continuous advancement of treatment options and the emergence of highly effective therapies, even “advanced breast cancer” no longer means there’s no hope.

6 Chemotherapy Sessions, 26 Radiotherapy Sessions, but the Tumor Worsened
Sandi (pseudonym), a 43-year-old woman from Indonesia, discovered a lump in her left breast two years ago, occasionally accompanied by pain. Medical examinations revealed a 3 cm mass with a high suspicion of malignancy. Following her local doctor’s advice, she underwent surgery. Post-operative pathology confirmed triple-negative breast cancer, with cancerous spread to the axillary lymph nodes.
To control disease progression, Sandi started intravenous chemotherapy. However, after the first cycle, she discovered she was pregnant and had to pause treatment. In 2024, one month after giving birth, she resumed therapy. Unfortunately, despite 6 cycles of chemotherapy and 26 sessions of radiotherapy, her condition worsened significantly—particularly the sternum area, where she developed a painful and enlarging mass.
She was told, “It’s nothing serious, just take some painkillers.” Dissatisfied with this diagnosis, Sandi traveled to Malaysia for further testing. PET-CT scans revealed widespread metastases throughout the body: bone, pleura, chest wall, subcutaneous scalp, and axillary lymph nodes.
From Chemotherapy Crisis to a Ray of Hope in China
Her first step was another round of chemotherapy. However, Sandi suffered a severe allergic reaction to the drugs. She lost consciousness, experienced heart failure, and had to be rushed to the ICU for emergency care. “I thought I wouldn’t live to see tomorrow,” she said, disheartened and hopeless.
Her husband never gave up. He sought medical advice everywhere, determined to find any chance of hope. Eventually, a glimmer of light appeared in Guangzhou, China. He contacted the Indonesia office of Fuda Cancer Hospital and, after consultation, decided to bring Sandi to Guangzhou for inpatient treatment.
Tumor Shrinks Nearly Half in Just Two Months
On April 13, 2025, Sandi arrived at Fuda’s Medical Department IV in a wheelchair. Her condition was poor. Though she could still get out of bed, she was extremely weak, suffering from chest tightness, shortness of breath, and right leg pain—unable to walk for long without resting. Further tests showed metastases not only in previously identified sites but also in the meninges and liver, along with a pulmonary artery embolism.
Given her high tumor burden and fragile condition—at risk of respiratory depression, worsening pulmonary embolism, and intracranial hemorrhage—Associate Chief Physician Dr. Xing Yanli quickly organized a multidisciplinary team and tailored a personalized treatment plan:
• For the pulmonary embolism and urinary tract infection: Symptomatic medication;
• For the chest wall mass: Biopsy and cryoablation, which confirmed breast cancer metastasis;
• For meningeal metastasis: Gamma Knife therapy was used instead of whole-brain radiotherapy due to her poor physical condition.
During treatment, Dr. Xing noticed Sandi tested positive for Her2 (low expression), meaning she could potentially benefit from ADC (antibody-drug conjugate) therapy. ADCs work by specifically binding to Her2 proteins on cancer cells, delivering cytotoxic agents directly, and triggering immune responses through antibody-dependent mechanisms.
After discussion and evaluation, the team administered ADC therapy combined with immunotherapy and targeted treatment.
To Sandi’s surprise, after just one cycle, visible tumor shrinkage occurred. After two cycles, follow-up scans showed significant reduction—nearly 50%—in the meningeal lesions, chest wall metastases, axillary lymph nodes, and liver tumors, achieving a partial response (PR).

△ Meningeal and subcutaneous metastasis: Before admission (left), after treatment (right)

△ Chest wall and sternum metastasis: Before (left), after (right)

△ Large liver metastasis: Before (left), after (right)

Sandi’s right leg pain disappeared. Her breathing and mobility improved dramatically—she no longer needed a wheelchair. “Thank God, thank Fuda!” she exclaimed. She deeply appreciated the professionalism and compassion of the medical team and now hopes to maintain her health and enjoy life to the fullest.

Cryoablation and NanoKnife: Cutting-Edge Tools in Precision Medicine
Sandi’s case is a successful example of combining cryoablation with Gamma Knife therapy, highlighting the vast potential of precision oncology in treating solid tumors. Fuda Cancer Hospital, one of the pioneers in multidisciplinary cancer care in China, continues to push the boundaries of patient outcomes using cryoablation and NanoKnife (IRE) technologies.

Cryoablation: A Minimally Invasive Freeze Against Cancer
Cryoablation inserts a probe into the tumor under image guidance. Using ultra-low temperatures (typically -140°C to -160°C), it freezes and destroys cancer cells within 15 minutes. This forms intracellular ice crystals, causing cell dehydration, membrane rupture, and cell death.

At Fuda, “visualized cryoablation” allows real-time monitoring of the ice ball to ensure complete tumor coverage while protecting nearby nerves and vessels. In Sandi’s case, her 5 cm chest wall mass was ablated with just two tiny punctures, leaving only small, rice-grain-sized scars.
Moreover, Fuda has been researching the immune-activating effects of cryoablation. Tumor antigens released from frozen cancer cells can stimulate the body’s immune response. A multicenter study at Fuda found that combining cryoablation with immune checkpoint inhibitors improved 3-year progression-free survival by 17% compared to ablation alone.

NanoKnife: Non-Thermal, Precision Ablation
NanoKnife (Irreversible Electroporation, IRE) delivers high-voltage pulses (1500–2500 volts) that last only 100 nanoseconds, creating nano-scale pores in cancer cell membranes. This causes cells to leak and die—without generating heat. Thus, it avoids damaging heat-sensitive structures like blood vessels and bile ducts, making it ideal for tumors near vital structures.

At Fuda, NanoKnife has proven particularly effective in pancreatic cancer—traditionally viewed as untreatable by ablation due to its proximity to major vessels. In Fuda’s cases, NanoKnife helped safely ablate tumors near the superior mesenteric artery, extending median survival to 22.8 months, nearly double that of traditional methods.

The Technical Matrix: Turning Despair into Possibility
Fuda has developed a comprehensive ablation matrix that includes cryoablation, NanoKnife, Gamma Knife, and seed implantation. For patients with widespread metastases like Sandi, customized treatment plans are based on tumor location, size, and blood supply:
• Superficial metastases (chest wall, scalp): Cryoablation for its excellent pain-relief effect;
• Lesions near central vessels (risk of pulmonary embolism): NanoKnife for precision ablation;
• CNS metastases (e.g., meninges): Gamma Knife for stereotactic radiotherapy.
This tailored approach has helped Fuda achieve an 83.7% local control rate, significantly higher than the 62.4% for single-technology treatments. Meanwhile, fusion imaging (PET-CT + enhanced MRI) helps doctors accurately target active tumors and avoid overtreatment.

From Personal Miracle to Collective Hope
Sandi’s story is not unique. Among 237 advanced breast cancer patients treated with cryoablation at Fuda, 48.6% experienced tumor downgrading, and 31.2% qualified for follow-up surgery. Most importantly, average quality of life (QOL) scores rose from 38 to 86 (out of 100) post-treatment.
In an ongoing prospective study involving 386 solid tumor patients, the combination of ablation and immunotherapy resulted in a 2-year overall survival rate of 61.4%, compared to 34.7% with chemotherapy alone. Behind these numbers are countless patients like Sandi who’ve found new light in the darkness.
As oncology enters an era of precision and personalization, Fuda Cancer Hospital is building bridges of hope for patients with advanced cancer. Sandi’s story is living proof: even when facing “advanced, full-body metastases,” life can still blossom through the power of modern medicine and unwavering determination.

🔗 Click to read more patient stories :
https://en.fudahospital.com/

📞 Contact us via:
Phone: +91 8850860970
WhatsApp: +91 8850860970
Website: https://fudahospital.in

26/06/2025

[Patient Story] [Thailand – Colon Cancer – localized Chemotherapy+PD-1]

Thailand Patient’s Tumor Gone After Localized Chemo + PD-1

Click to learn more patient stories:
https://en.fudahospital.com/fudanews/latestnews

You can contact us through the following channels:
☎️ TEL: +91 8850860970
🌟 WhatsApp: +91 8850860970
🌍 Website: https://fudahospital.in/

21/06/2025

[Minimally Invasive Treatment] [Pancreatic Cancer – NanoKnife]

NanoKnife: “Electric Blade” Tackles Tumors in Forbidden Zones

Surgical resection is the primary treatment for most malignant tumors. But what if the tumor is in a complex or critical area—wrapped around blood vessels, invading nerves, adjacent to vital structures, or in a location too complex for surgery?
Take the so-called "king of cancers"—pancreatic cancer—as an example. Due to the pancreas’s deep and complex anatomical location, surgery is challenging. Moreover, many cases are diagnosed at a late stage, resulting in a 5-year survival rate that remains dismally low. Fewer than 20% of patients are eligible for surgery at the time of diagnosis.

In many cases, pancreatic tumors encase vital blood vessels such as the superior mesenteric artery and vein, or the celiac artery, making surgery highly risky and technically difficult. While radiotherapy or chemotherapy are often used, pancreatic cancer is not very responsive to either, and patient prognosis remains poor.
Traditional thermal ablation techniques—like radiofrequency ablation, microwave ablation, and cryoablation—damage both tumor and nearby tissue indiscriminately. Because they rely on temperature-based destruction, these methods often harm surrounding structures, potentially causing severe complications.
This is where a new, non-thermal, selective, and tissue-sparing technology comes in—NanoKnife Ablation.

The scientific term for NanoKnife is Irreversible Electroporation (IRE). It uses high-voltage, microsecond-length electric pulses to create permanent nanopores in tumor cell membranes, triggering cell death while preserving critical structures. Unlike traditional surgery, NanoKnife minimizes risks such as bleeding and allows physicians to "have their cake and eat it too."

NanoKnife technology uses 3000-volt short electrical pulses to perforate the tumor cell membrane. Electro-pulse patterns are clearly visible on ECG during treatment. It is highly effective for pancreatic cancer and hilar liver cancer.
Recent studies show promising results:
• Martin et al. reported over 200 pancreatic cancer patients treated with NanoKnife with overall survival (OS) exceeding 2 years.
• A multicenter international study showed an OS of 30 months.
• An Asian multicenter trial combining S1 chemotherapy with IRE showed an OS of 28.7 months.
Due to such encouraging outcomes, China’s National Health Commission has included irreversible electroporation in the 2022 Pancreatic Cancer Diagnosis and Treatment Guidelines. Several international consensus statements and clinical guidelines also recommend its use.

A pancreatic cancer patient from the Philippines, who could not undergo surgery and had a biliary stent placed locally, traveled to China specifically for NanoKnife treatment. The patient had a 5.3 cm tumor in the pancreatic head—complex and difficult to treat. Under ultrasound and CT guidance, we used a mobile ablation approach to successfully complete NanoKnife ablation.
NanoKnife also shows significant advantages for tumors near delicate areas such as:
• Liver hilum
• Bile ducts
• Gallbladder
• Ureters
Tumors in the liver hilum are nearly impossible to remove surgically, and thermal ablation is risky due to potential damage to essential hepatic structures. Why can NanoKnife preserve bile ducts, pancreatic ducts, blood vessels, and even the intestines, ensuring faster functional recovery post-treatment?

Because NanoKnife doesn’t rely on heat. Instead, it uses high-frequency electrical pulses to induce cell death without destroying anatomical structures, avoiding the risks of incomplete ablation or thermal injury.
Professor Anna from the University of Rome led a literature review and meta-analysis on NanoKnife for hilar cholangiocarcinoma. After screening 627 articles, six studies were selected for detailed quantitative analysis.

Key findings:
• NanoKnife + chemotherapy: Average survival time of 25 months.
• 100% bile duct recanalization rate, indicating significantly improved quality of life.
Even with certain limitations, the survival benefit for patients with unresectable hilar cholangiocarcinoma was substantial.
One of the cited studies came from our hospital—the first in the world to propose a synchronous NanoKnife + chemotherapy protocol. This method enhances the tumor-killing effects of NanoKnife while leveraging its electrochemical and immune-modulating benefits. This combined approach offers synergistic efficacy, especially for cancers that are traditionally hard to ablate—similar in concept to chemoradiotherapy, but safer and more effective.

For prostate tumors, traditional ablation methods can damage nerves and result in sexual dysfunction. NanoKnife, by preserving nerves and ducts, offers an irreplaceable option for these patients.

NanoKnife ablation offers a new and effective local treatment for malignant tumors in anatomically challenging and surgically inaccessible regions.

Click to explore more patient stories:
https://en.fudahospital.com/

Contact us:
☎️ Phone: +91 8850860970
🌟 WhatsApp: +91 8850860970

🌍 Website: https://fudahospital.in

18/06/2025

[Patient Story] [China – Breast Cancer – Local Interventional Chemotherapy]

Age 23, Advanced Breast Cancer Diagnosed
Breast Lump → Late-Stage Breast Cancer

Her name is Xu. She had just celebrated her 23rd birthday when she was diagnosed with advanced breast cancer in June 2024. In fact, a lump had appeared in her right breast as early as June 2023, but since it wasn’t painful, she didn’t take it seriously.
By 2024, Xu began experiencing chest and back pain, along with pain in her ribs. Coincidentally, she had just started working out around that time, so her parents thought the discomfort was due to muscle strain or lactic acid buildup. However, the pain worsened and was accompanied by recurrent fevers. When she finally went to the local hospital for a check-up, the diagnosis was devastating: right breast cancer with metastases to the right axillary and left supraclavicular lymph nodes, multiple bone metastases, and liver metastases. A biopsy confirmed it was invasive ductal carcinoma (Stage IV).

“At first, my parents hid the truth from me, afraid I wouldn’t be able to handle it,” said Xu.
She only learned the truth after the persistent bone pain and recurring fevers made sleep impossible. Just as her parents had feared, Xu found it hard to accept that she had advanced cancer in her early twenties.

Breast Cancer Is Not Just for “Older People”
Although women aged 45–55 are at the highest risk for breast cancer in China, it doesn’t mean younger women are entirely safe. In clinical practice, there are many young patients like Xu.
So, why do some women develop breast cancer at such a young age?
Aside from genetic predisposition, the rising incidence of breast cancer in younger women is closely linked to modern lifestyles. Long-term sleep deprivation, high work stress, irregular eating habits, and lack of exercise can all lead to hormonal imbalances, increasing the risk of breast cancer.
In Xu’s case, her lifestyle was particularly unhealthy:
• She worked under heavy pressure, often returning home after 11 p.m.
• Rarely ate at home and mostly relied on takeout.
• Frequently stayed up late, sleeping around 1 or 2 a.m.
• Often bottled up emotions and argued with her parents...
The accumulation of these risk factors ultimately led to her breast cancer diagnosis. Therefore, young women are advised to maintain a healthy routine and balanced diet, and manage stress effectively.
With limited knowledge about cancer, Xu’s parents searched for information and medical advice from various sources. She eventually received a combination of targeted therapy and endocrine therapy at a local hospital. Follow-up scans showed a reduction in the tumor size.
However, considering her young age and the fact that she was unmarried and had no children, Xu chose to discontinue treatment after four cycles and instead opted for traditional Chinese medicine to nourish her blood and boost her immune system.

Multidisciplinary Internal Medicine Treatment to Counter Multiple Lesions
At the beginning of 2025, Xu's recurring fevers and worsening lower back pain severely impacted her mobility — she had to rely on a wheelchair to get around. Realizing that Chinese medicine alone was insufficient, her parents sought further help and managed to book an appointment with Dr. Niu Lizhi, the President of Fuda Cancer Hospital in Guangzhou. In February, Xu was admitted to Medical Oncology Department IV.
“A high-metabolism tumor was found in the right breast, along with multiple bone metastases and widespread lymph node metastases…”
When Dr. Niu and her attending physician Dr. Yang Ting saw Xu enter the consultation room with the support of her parents, they were heartbroken. They were determined to help her return to a normal life through scientifically based, personalized treatment.
Based on her medical history and genetic test results, and with full consent from Xu and her family, the medical team proposed a comprehensive anti-cancer plan: chemotherapy combined with targeted therapy to control systemic tumors.
For the breast lesion on the right side, minimally invasive treatment was scheduled based on her condition. To treat bone metastases, she was given denosumab to protect bone health. As for spinal metastases that were causing progressive muscle weakness in her lower limbs, Xu and her family declined radiotherapy, so she continued with internal medicine anti-tumor treatment and supportive care.
• After the first cycle, the lymph node metastasis in her right armpit shrank significantly, bone pain eased, and she could walk with the support of a brace.
• After the second cycle, pain in her lower back, upper back, and sternum improved noticeably.
• After the third cycle, her tumor markers returned to normal, and the breast mass became smaller and softer.…
By the fifth cycle, everyone received the thrilling news: The previously high-metabolic tumor lesions throughout her body had significantly reduced or even disappeared. Her primary breast tumor, multiple bone metastases, and lymph node metastases had all shrunk dramatically. The cancer activity was nearly completely suppressed.

Before and After Treatment

Upon learning from her test results that her tumors had regressed, Xu and her family were overwhelmed with emotion. Tears of joy flowed as they hugged Dr. Yang Ting, expressing heartfelt gratitude again and again. To them, Dr. Yang’s gentle voice and comforting presence had lifted the cloud of pain and despair.
It was thanks to Fuda’s multidisciplinary medical team, the individualized and precise treatment plan developed by Department IV, and the wholehearted efforts of the entire staff that Xu was able to recover so quickly and embrace a healthier, brighter future.

This moment of recovery is certainly worth celebrating, but we must also recognize that cancer prevention and control is a long-term battle. To prevent recurrence or disease progression, Xu and her family must remain vigilant, strictly follow medical advice, complete follow-up treatments on schedule, and attend regular check-ups.
An optimistic mindset is the foundation for lasting recovery and health. Only by transforming the joy of recovery into ongoing scientific management and a healthy lifestyle can true and lasting well-being be achieved.

Click to learn more patient stories:
https://en.fudahospital.com/

You can contact us through the following channels:
☎️ TEL: +91 8850860970
🌟 WhatsApp: +91 8850860970
🌍 Website: https://fudahospital.in/

Address

Vile Parle

Opening Hours

Monday	10:30am - 6pm
Tuesday	10:30am - 6pm
Wednesday	10:30am - 6pm
Thursday	10:30am - 6pm
Friday	10:30am - 6pm
Saturday	10:30am - 6pm

Telephone

+918850860970

Website

http://www.fudahospital.in/

Alerts

Be the first to know and let us send you an email when Fuda Cancer Hospital - India posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Fuda Cancer Hospital - India:

Shortcuts

Our Story

Fuda is committed to providing cancer patients around the world with the best medical care.

Fuda Cancer Hospital is considered one of the BEST cancer hospitals in China by patients and is affiliated to Jinan University and Translational Medicine Center of Guangzhou Institute of Biomedicine and Health of Chinese Academy of Sciences. As a tertiary hospital, Fuda operates with international standards and was selected as the National Key Clinical Specialty (Oncology) in 2010. In 2014, Fuda was accredited by the Joint Commission International (JCI), a golden standard of medical service worldwide. Fuda is equipped with 400 beds, 45 VIP rooms and 500 medical staffs to help our patients.

Cancer treatment varies from patient to patient. Multiple Disciplinary Teams work in Fuda to personalize treatment for every single patient. Those teams include NanoKnife Ablation team (Irreversible Electroporation), Cryosurgical ablation team, cancer micro-vascular intervention team, combined immunotherapy team, and surgical team. Our clinical achievement and academic research are widely accepted by peer doctors and scientific journals. In Fuda, Doctors use more than 20 types of cancer treatment, including those mentioned above, to help our patient LIVE WITH CANCER as long as possible with a quality life.

Fuda highly focuses on research and application of advanced clinical procedures and pays tremendous attention on patient care. In the past two decades, Fuda has been active in promoting Minimally Invasive Treatments such as Cryosurgery, NanoKnife, micro-vascular intervention treatment and Brachytherapy. Fuda was the first in China to introduce NanoKnife for clinical use and has accumulated substantial clinical experience. Patients are not just receiving treatment in Fuda, they live a life in Fuda with their family.